Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. Wegovy was first to market but ...